Tempo Therapeutics, Inc. received a $1 million cooperative agreement from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a multivalent vaccine platform to provide durable immunity against multiple coronaviruses. Specifically, the funding will support Tempo Therapeutics' efforts to determine the optimal dose, assess durability of immune response, evaluate protective immunity against SARS-CoV-2 variants, and develop a regulatory plan for their single-dose multivalent vaccine (VAXMAP) that aims to produce durable and cross-reactive immunity against various coronaviruses. If successful, VAXMAP could help address limitations of current COVID-19 vaccines such as diminished efficacy against variants and cold chain distribution challenges. The award period is from June 15, 2023 through May 31, 2025.
Generated 3/20/24, 7:52 AM